Investment Summary

Exits Pharmion

On November 6, 2003, invested in life science company Pharmion from Bay City Capital and Nexus Life Science Partners

Investment Highlights
  • This is transaction in the Life Science sector.
  • This is transaction in the United States.
  • This is transaction in Colorado.
Investment Fate
  • Pharmion was sold to a strategic buyer in 2007 for 2.9B USD.

Investment Summary

Date 2003-11-06
Target Pharmion
Sector Life Science
Sellers(s) Bay City Capital
Nexus Life Science Partners
Deal Type IPO

Target

Pharmion

Boulder, Colorado, United States
website
Pharmion Corporation is a global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza®, a DNA demethylating agent.

Search 177,729 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Seller(S) 2

SELLER

Bay City Capital

San Rafael, California, United States

Investor Investor Investor Investor Investor

website


Category Venture Capital Firm
Founded 1997
PE ASSETS 1.3B USD
Size Large
Type Sector Focused
DESCRIPTION

Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.


DEAL STATS #
Overall 11 of 62
Sector (Life Science) 8 of 45
Type (IPO) 6 of 23
State (Colorado) 2 of 2
Country (United States) 11 of 59
Year (2003) 3 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2003-02-18 Maxia Pharmaceutical

San Diego, California, United States

Maxia Pharmaceutical, Inc. is a pharmaceutical company focused on small molecule drugs that target major diseases such as cancer and metabolic disorders.

Sell $42M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2003-11-20 Oculex Pharmaceuticals

Sunnyvale, California, United States

Oculex Pharmaceuticals, Inc. is an Ophthalmic drug delivery company.

Sell $230M
SELLER

Nexus Life Science Partners

New York, New York, United States

website


Category Growth Capital Firm
Founded 2001
Size Small
Type Sector Focused
DESCRIPTION

Nexus Life Science Partners is a private equity firm that targets private and public healthcare companies located within the United States and around the world. The Firm's focus is on the growth segments of the healthcare industry. In particular, Nexus looks for product-driven life sciences companies developing breakthrough therapeutics for clinical needs, positively altering disease course and associated costs. The firm seeks for each private investment a potential for liquidity within 24 months after initial investment, as well as a 2-3 times return on invested capital. Nexus Life Science Partners was formed in 2001, and is based in New York, New York.


DEAL STATS #
Overall 1 of 22
Sector (Life Science) 1 of 18
Type (IPO) 1 of 6
State (Colorado) 1 of 1
Country (United States) 1 of 19
Year (2003) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2002-06-01 Calypso Medical Technologies

Seattle, Washington, United States

Calypso Medical Technologies, Inc. is a medical device company.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2004-02-27 Pharmacopeia

Cranbury, New Jersey, United States

Pharmacopeia, Inc. is a Drug Discovery identifying and developing small molecule drug candidates, with a primary focus on immunological diseases.

Sell -